On May 19, 2023, 贝博体育 (stock code: 1875.HK) announced a strategic cooperation was established with BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay). Dr. Haibin Wang, CEO of BioRay, and Dr. Jun Liu, CEO of 贝博体育 attended the signing ceremony. With a one-stop, end-to-end CDMO service platform, 贝博体育 will provide comprehensive support to BioRay for its multiple R&D projects, helping BioRay to develop antibody-drug conjugate (贝博体育) pipeline from R&D to IND, and future clinical approval and commercial production.
According to the agreement, 贝博体育 will provide one-stop CDMO services for multiple 贝博体育 development projects as CDMO partner, covering 贝博体育 drug development, process development, analytical method development, conjugated drug development, as well as clinical and commercial production.
Dr. Haibin Wang, CEO of BioRay, said:“We are very glad to enter into a strategic collaboration with 贝博体育. Focusing on the two therapeutic areas of autoimmunity and tumor immunity, Bioray has built a comprehensive and in-depth innovation pipeline and is committed to providing an entire and diverse product portfolio. This strategic collaboration with 贝博体育 will further leverage the synergies between the two companies in the field of antibody drug conjugates. The one-stop 贝博体育 development platform of 贝博体育 will not only reduce the risk of resource crossover and regulatory risks associated with segmented manufacturing, accelerate the launch of 贝博体育 drugs, but will also help Bioray to build multiple immune pipelines in a comprehensive manner, thus avoiding homogeneous competition and bringing benefit to more patients.”
Dr. Jun Liu, CEO of 贝博体育, said:"We are very glad to establish strategic collaboration with Bioray, a first-class innovative drug company. Bioray is an innovative biopharmaceutical company focusing on autoimmunity and oncology, with expertise and innovation in all aspects of R&D. It has launched multiple drugs and pipelines under development which are also highly anticipated by the industry. 贝博体育 is one of the few companies that have several complete commercial production lines of antibodies and 贝博体育, and also one of the leading one-stop 贝博体育 CDMO service companies in the world that integrates antibody intermediate, 贝博体育 DS and 贝博体育 DP. On the other hand, 贝博体育 has accumulated comprehensive experience in drug process development, clinical research, product launch and commercialization over more than 10 years’ development, and currently has two drugs in commercial production in our Suzhou plant. The quality system is continuously regulated by national regulations and passed the EU QP audit with zero defects last year. These may increase the quality and speed of several 贝博体育 drug development projects by Bioray. In the future, both parties will work together to deepen the cooperation from R&D, to clinical and commercial production of 贝博体育 drugs to promote the rapid development of the 贝博体育 industry.”